HB Fuller Company formulates, manufactures and markets adhesives, sealants, coatings, polymers, tapes, encapsulants, additives and other specialty chemicals worldwide. The company is headquartered in Saint Paul, Minnesota.
272 articles
H.B. Fuller prices $850 million in senior unsecured notes to finance the acquisition of Advanced Medical Solutions Group plc. This strategic move aims to expand the company's specialty chemicals exper
H.B. Fuller has priced $850 million of senior unsecured notes due in 2034 at a 7.625% interest rate through a private offering to secure long-term debt financing.
H.B. Fuller priced an $850 million senior notes offering at 7.625%, intending to use proceeds to acquire Advanced Medical Solutions Group plc and refinance debt. The transaction includes a contingency
H.B. Fuller priced $850 million in senior unsecured notes due 2034. Proceeds will fund the acquisition of Advanced Medical Solutions Group plc, repay debt, and support general corporate purposes.
An H.B. Fuller insider purchased $500,000 worth of shares per a recent SEC filing, while the board continues to reject acquisition attempts by Ancora Holdings Group for its Building Adhesive Solutions
H.B. Fuller director R. Jeffrey Bailly bought 10,000 shares at $50 each through a trust on October 7, 2026, according to SEC filings. The move signals positive insider sentiment for the adhesive and c
HB Fuller Company filed a Form 4 with the SEC on October 6, as reported by Investing.com.
H.B. Fuller Sr. VP Gregory O. Ogunsanya converted stock units into common shares on October 4, 2026, with 202 shares withheld for taxes.
H.B. Fuller issued $950 million in senior unsecured notes to finance the acquisition of Advanced Medical Solutions Group plc, with provisions for redemption if the deal fails to close by the outside d
Analysts set H.B. Fuller's consensus target at $64.62 with a 'Moderate Buy' rating after an EPS beat and 5.2% revenue rise. Insider buying signals confidence in the chemical firm's outlook.
HB Fuller Company director R. Jeffrey Bailly received 1,300 restricted stock units on September 30, 2026, converting to common stock with an expiration date of September 30, 2029.
H. B. Fuller Company announced a quarterly dividend of $0.245 per share, marking its 57th consecutive year of dividend increases. The specialty chemicals firm also reported strong quarterly EPS of $1.
H.B. Fuller board member Srilata Zaheer bought 2,040 shares worth over $100,000, indicating confidence in the adhesive manufacturer despite revenue challenges. The insider purchase reflects an attract
H.B. Fuller Co director Michael Happe purchased 2,000 shares worth approximately $99,260, increasing his total holdings. The adhesive and specialty chemical firm views this insider buying as a positiv
H.B. Fuller director Michael Happe purchased 2,000 shares, increasing ownership by 149%, while the company reported quarterly earnings per share of $1.52 despite revenue falling short of expectations.
H.B. Fuller director Srilata Zaheer purchased 2,000 shares, increasing ownership by 148%, while the company reported better-than-expected quarterly EPS of $1.52 and 5.2% revenue growth.
H.B. Fuller director Thomas Handley purchased $98,820 worth of shares while the stock traded near its 52-week low. Despite better-than-expected adjusted earnings, revenue misses led Baird to lower its
H.B. Fuller director Charles T. Lauber purchased 2,005 shares totaling $99,984 as the stock trades near its 52-week low. His direct holdings now exceed 16,000 shares plus convertible units.
Ancora Holdings submitted an enhanced proposal to acquire H.B. Fuller's Building Adhesive Solutions segment for $1.2 billion to $1.4 billion in cash, backed by debt financing from Fortress Investment
Activist investor Ancora Holdings raised its bid for H.B. Fuller's Building Adhesive Solutions unit to $1.2–$1.4 billion. The deal, backed by Fortress Investment Group, aims to help H.B. Fuller reduce
Ancora raised its cash offer for H.B. Fuller's building adhesives business to up to $1.4 billion after securing debt financing from Fortress Investment Group. The activist move follows H.B. Fuller's r
Activist investor Ancora Holdings increased its bid for H.B. Fuller's building adhesives unit to between $1.2 billion and $1.4 billion after the company rejected the initial offer. The deal aims to ac
H.B. Fuller appointed R. Jeffrey Bailly to its board to enhance medical technology expertise, aligning with a focus on higher-margin healthcare exposure while facing activist investor pressure for a s
Cleveland-based activist investor Ancora has raised its bid for H.B. Fuller's building unit, according to a September 29 Bloomberg report detailing ongoing efforts regarding the specialty chemicals co
H.B. Fuller appointed R. Jeffrey Bailly to its Board of Directors to leverage his manufacturing and medical technology expertise. The appointment supports the company's strategic shift toward higher-m
H.B. Fuller reported Q3 2026 revenue of $938 million and adjusted EBITDA of $187 million. The company raised its full-year EBITDA outlook to $655–$670 million and noted an anticipated AMS acquisition.
H.B. Fuller reported a 5.2% revenue increase and 21% EPS surge for Q3, raising guidance with $75 million in planned annualized cost savings by 2030. However, declining demand and acquisition leverage
H.B. Fuller reported strong Q3 2026 results with $1.52 EPS and $938.2 million revenue, exceeding Wall Street expectations. Management issued full-year adjusted EPS guidance of $4.70 to $4.85, citing c
H. B. Fuller reported strong Q3 fiscal 2026 results with revenue up 5.2% and EBITDA up 9%, driven by pricing strategies despite high raw material costs. The company also plans to acquire Advanced Medi
H.B. Fuller shares declined following its fiscal third-quarter earnings report, where the chemical company missed net revenue expectations despite beating adjusted profit estimates amid guidance conce
ChemBrief